Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial ovarian cancer. OBJECTIVE: This study aimed to provide a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellier, Charlotte, Gladieff, Laurence, Le Du, Fanny, Berton, Dominique, Bonnard, Charlotte, Suau, Delphine, Richard, Anne-Céline, Brenner, Ophélie, Lahouegue, Amir, Freyer, Gilles, Floquet, Anne, Frank, Sophie, Kfoury, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232683/
https://www.ncbi.nlm.nih.gov/pubmed/36630055
http://dx.doi.org/10.1007/s40801-022-00349-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232683/
https://www.ncbi.nlm.nih.gov/pubmed/36630055
http://dx.doi.org/10.1007/s40801-022-00349-9

Ejemplares similares